Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
372 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07191418 | Study-group on Palliative ERCP And RFA-ablation in Metastatic and Inoperable Pancreatic Tumors(Spearmint) | recruiting | N/A | 178 | Roberto ValenteOTHER_GOV | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06499285 | A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions | recruiting | Phase 3 | 225 | TakedaINDUSTRY | 26 | Aug 21, 2026 |
| NCT07209111 | A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)(KANDLELIT-014) | recruiting | Phase 2 | 150 | Merck Sharp & Dohme LLCINDUSTRY | 19 | Aug 21, 2026 | clinicaltrials |
| NCT05945732 | DESTINY Breast Respond HER2-(Ultra)Low Europe | recruiting | — | 2,295 | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyINDUSTRY | 10 | Aug 19, 2026 | clinicaltrials |
| NCT06869629 | Omission of Axillary Lymph Node Dissection in Case of Tumor Spread to Lymph Nodes in the Armpit in Breast Cancer(SENOMAC-ULTRA) | recruiting | N/A | 1,380 | Karolinska InstitutetOTHER | 3 | Aug 17, 2026 | clinicaltrials |
| NCT07764978 | Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT(DURGA-5) | recruiting | Phase 3 | 750 | AstraZenecaINDUSTRY | 15 | Aug 14, 2026 | clinicaltrials |
| NCT03911128 | A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia | recruiting | — | 500 | Mats HeymanOTHER | 8 | Aug 13, 2026 | clinicaltrials |
| NCT05476939 | Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0(BIOMEDE 2) | recruiting | Phase 3 | 433 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 6 | Aug 13, 2026 | clinicaltrials |
| NCT02300766 | Cerebellar Mutism Syndrome Study | recruiting | — | 2,000 | Rigshospitalet, DenmarkOTHER | 14 | Aug 12, 2026 | clinicaltrials |
| NCT04307576 | A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia | recruiting | Phase 3 | 6,430 | Mats HeymanOTHER | 15 | Aug 12, 2026 | clinicaltrials |
| NCT05417594 | Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies(CERTIS1) | recruiting | Phase 1 / Phase 2 | 695 | AstraZenecaINDUSTRY | 7 | Aug 12, 2026 | clinicaltrials |
| NCT07502820 | The POWER Trial: Personalised Dose Optimisation With Adjuvant Tamoxifen Therapy in Breast cancER(POWER) | recruiting | Phase 3 | 1,100 | Karolinska InstitutetOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06687291 | Cognitive Impact Associated With Surgery For Gastric Or Esophageal Cancer(CASE) | recruiting | — | 130 | Karolinska InstitutetOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04525989 | Preoperative Short-Course Radiation Therapy With PROtons Compared to Photons In High-Risk RECTal Cancer (PRORECT)(PRORECT) | recruiting | N/A | 254 | Alexander ValdmanOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06501053 | Contact Radiotherapy for Rectal Cancer(CORRECT) | recruiting | N/A | 110 | Alexander ValdmanOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06926868 | A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) | recruiting | Phase 2 / Phase 3 | 600 | Bristol-Myers SquibbINDUSTRY | 28 | Aug 10, 2026 | clinicaltrials |
| NCT07754500 | Deep Optical Imaging of Tissue (DOIT)(DOIT) | recruiting | N/A | 60 | Lund UniversityOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT03719547 | Robot-assisted Approach to Cervical Cancer(RACC) | recruiting | N/A | 800 | Karolinska InstitutetOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT02102165 | AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.(AURORA) | recruiting | N/A | 1,000 | Jules Bordet InstituteOTHER | 10 | Aug 6, 2026 | clinicaltrials |
| NCT04077307 | A Study in Leukemia Patients With Karonudib(MAATEO) | recruiting | Phase 1 | 50 | Thomas Helleday FoundationOTHER | 3 | Aug 6, 2026 | clinicaltrials |
| NCT06644781 | A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) | recruiting | Phase 3 | 510 | Daiichi SankyoINDUSTRY | 17 | Aug 4, 2026 | clinicaltrials |
| NCT06877637 | On-treatment Surveillance of Tumor Evolution and Response to Systemic Treatment in Bile Duct and Liver Cancer(BILLIONSTARS) | recruiting | — | 150 | Region SkaneOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06885034 | A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201) | recruiting | Phase 1 / Phase 2 | 451 | GlaxoSmithKlineINDUSTRY | 19 | Aug 3, 2026 | clinicaltrials |
| NCT01804686 | A Long-term Extension Study of PCI-32765 (Ibrutinib)(CAN3001) | recruiting | Phase 3 | 700 | Janssen Research & Development, LLCINDUSTRY | 30 | Jul 31, 2026 | clinicaltrials |
| NCT07607366 | Effects of Negative Pressure Wound Bandaging After Mastectomy(NEPTAM) | recruiting | N/A | 76 | Dalarna County Council, SwedenOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07106762 | Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy | recruiting | Phase 2 / Phase 3 | 470 | Bristol-Myers SquibbINDUSTRY | 22 | Jul 29, 2026 | clinicaltrials |
| NCT04951622 | A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis | recruiting | Phase 3 | 199 | Janssen Research & Development, LLCINDUSTRY | 17 | Jul 27, 2026 | clinicaltrials |
| NCT05503797 | A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations | recruiting | Phase 2 | 254 | Fore BiotherapeuticsINDUSTRY | 12 | Jul 27, 2026 | clinicaltrials |
| NCT03934372 | Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors | recruiting | Phase 1 / Phase 2 | 70 | Incyte Biosciences International SàrlINDUSTRY | 7 | Jul 23, 2026 | clinicaltrials |
| NCT06131840 | A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | recruiting | Phase 1 | 914 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 10 | Jul 22, 2026 | clinicaltrials |
| NCT07218809 | AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer(TREVI-OC-01) | recruiting | Phase 3 | 1,100 | AstraZenecaINDUSTRY | 24 | Jul 21, 2026 | clinicaltrials |
| NCT03583710 | Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence | recruiting | Phase 3 | 240 | M.D. Anderson Cancer CenterOTHER | 5 | Jul 16, 2026 | clinicaltrials |
| NCT05327894 | Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia(Interfant-21) | recruiting | Phase 3 | 160 | Princess Maxima Center for Pediatric OncologyOTHER | 24 | Jul 10, 2026 | clinicaltrials |
| NCT06217822 | First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)(PAnTHA) | recruiting | Phase 1 | 198 | BayerINDUSTRY | 10 | Jul 7, 2026 | clinicaltrials |
| NCT06796907 | A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2) | recruiting | Phase 1 / Phase 2 | 305 | GlaxoSmithKlineINDUSTRY | 23 | Jul 7, 2026 | clinicaltrials |
| NCT07304271 | Intraperitoneal Paclitaxel and Systemic Therapy Versus Systemic Therapy Alone in Gastric Cancer Patients With Peritoneal Metastasis(IPa-Gastric) | recruiting | Phase 3 | 262 | Magnus NilssonOTHER | 3 | Jul 7, 2026 | clinicaltrials |
| NCT02332668 | A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) | recruiting | Phase 1 / Phase 2 | 370 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Jul 6, 2026 | clinicaltrials |
| NCT07535112 | A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation | recruiting | Phase 1 | 130 | BayerINDUSTRY | 10 | Jul 6, 2026 | clinicaltrials |
| NCT06819007 | Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)(DO-01) | recruiting | Phase 3 | 582 | Daiichi SankyoINDUSTRY | 25 | Jul 2, 2026 | clinicaltrials |
| NCT04064060 | A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials | recruiting | Phase 3 | 665 | CelgeneINDUSTRY | 22 | Jul 1, 2026 | clinicaltrials |
| NCT06246149 | Adjuvant Tebentafusp in High Risk Ocular Melanoma(ATOM) | recruiting | Phase 3 | 290 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Jun 30, 2026 | clinicaltrials |
| NCT06716814 | Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa(LIBERTY) | recruiting | Phase 3 | 104 | Swedish Orphan BiovitrumINDUSTRY | 7 | Jun 26, 2026 | clinicaltrials |
| NCT04219254 | A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 197 | BioInvent International ABINDUSTRY | 7 | Jun 25, 2026 | clinicaltrials |
| NCT06431594 | A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1) | recruiting | Phase 1 | 675 | GlaxoSmithKlineINDUSTRY | 15 | Jun 25, 2026 | clinicaltrials |
| NCT04068597 | Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | recruiting | Phase 1 / Phase 2 | 250 | CellCentric Ltd.INDUSTRY | 5 | Jun 24, 2026 | clinicaltrials |
| NCT00196742 | Fabry Disease Registry & Pregnancy Sub-registry | recruiting | — | 9,000 | Genzyme, a Sanofi CompanyINDUSTRY | 44 | Jun 23, 2026 | clinicaltrials |
| NCT07219238 | Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) | recruiting | Phase 2 / Phase 3 | 175 | GE HealthcareINDUSTRY | 2 | Jun 17, 2026 | clinicaltrials |
| NCT05208047 | (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors | recruiting | Phase 3 | 482 | Cogent Biosciences, Inc.INDUSTRY | 22 | Jun 16, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials